Cephalon and Mesoblast sign regenerative medicines deal worth more than $2 billion
This article was originally published in Scrip
Cephalon of the US has acquired almost 20% of Mesoblast and bought the rights to develop the Australian company's adult stem cell technology to treat certain cardiovascular, central nervous system (CNS) and oncology conditions in a deal that could be worth more than $2 billion to Mesoblast.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.